822 related articles for article (PubMed ID: 33165832)
1. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Crosas B
Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitination and deubiquitination: Implications on cancer therapy.
Dagar G; Kumar R; Yadav KK; Singh M; Pandita TK
Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194979. PubMed ID: 37633647
[TBL] [Abstract][Full Text] [Related]
5. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
[TBL] [Abstract][Full Text] [Related]
6. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
7. Targeting Deubiquitinating Enzymes and Autophagy in Cancer.
Mooneyham A; Bazzaro M
Methods Mol Biol; 2017; 1513():49-59. PubMed ID: 27807830
[TBL] [Abstract][Full Text] [Related]
8. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Landré V; Rotblat B; Melino S; Bernassola F; Melino G
Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
[TBL] [Abstract][Full Text] [Related]
9. The role of the ubiquitin-proteasome pathway in cancer development and treatment.
Ding F; Xiao H; Wang M; Xie X; Hu F
Front Biosci (Landmark Ed); 2014 Jun; 19(6):886-95. PubMed ID: 24896323
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
11. NEDD4: a promising target for cancer therapy.
Ye X; Wang L; Shang B; Wang Z; Wei W
Curr Cancer Drug Targets; 2014; 14(6):549-56. PubMed ID: 25088038
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.
Chen YJ; Wu H; Shen XZ
Cancer Lett; 2016 Sep; 379(2):245-52. PubMed ID: 26193663
[TBL] [Abstract][Full Text] [Related]
13. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
14. The 26S proteasome is a multifaceted target for anti-cancer therapies.
Grigoreva TA; Tribulovich VG; Garabadzhiu AV; Melino G; Barlev NA
Oncotarget; 2015 Sep; 6(28):24733-49. PubMed ID: 26295307
[TBL] [Abstract][Full Text] [Related]
15. Proteasome-associated deubiquitinases and cancer.
Mofers A; Pellegrini P; Linder S; D'Arcy P
Cancer Metastasis Rev; 2017 Dec; 36(4):635-653. PubMed ID: 29134486
[TBL] [Abstract][Full Text] [Related]
16. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinating enzymes as therapeutic targets in cancer.
Lim KH; Baek KH
Curr Pharm Des; 2013; 19(22):4039-52. PubMed ID: 23181570
[TBL] [Abstract][Full Text] [Related]
18. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Driscoll JJ; Dechowdhury R
Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
[TBL] [Abstract][Full Text] [Related]
19. Proteasome substrate receptors and their therapeutic potential.
Osei-Amponsa V; Walters KJ
Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
[TBL] [Abstract][Full Text] [Related]
20. Targeting the ubiquitin proteasome system: beyond proteasome inhibition.
Xolalpa W; Perez-Galan P; Rodríguez MS; Roué G
Curr Pharm Des; 2013; 19(22):4053-93. PubMed ID: 23181575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
